116-52-9

Usage

Uses

Used in Veterinary Medicine:
Dicloralurea is used as a food additive in veterinary medicine to promote growth and improve feed efficiency in animals.
Used in Chemical Synthesis:
Dicloralurea is used in the preparation of monoaromatic derivatives of pulvinic acids, which may exhibit antioxidant properties and have potential applications in various industries.
Used in Pesticide Formulation:
Dicloralurea was previously used as a component of early pesticides, although its use has since been discontinued due to environmental and health concerns.

InChI:InChI=1/C5H6Cl6N2O3/c6-4(7,8)1(14)12-3(16)13-2(15)5(9,10)11/h1-2,14-15H,(H2,12,13,16)

Upstream product

• 75-87-6 chloral 
• 57-13-6 urea 
• 302-17-0 chloral hydrate 
• 13598-36-2 phosphonic Acid 
• 58695-41-3 N-cyclohexylglycine 
• 107492-16-0 (S)-2-<oxy>-6-<<(phenylmethoxy)carbonyl>amino>hexanoic acid 
• 121-44-8 triethylamine 
• 88982-59-6 2,2,2-Trichlor-1-hydroxy-ethylisocyanat 

Downstream Products

• 64989-02-2 N,N'-bis-(1-acetoxy-2,2,2-trichloro-ethyl)-urea 
• 67-66-3 chloroform 
• 3392-07-2 tert-butyl N-{2-[(2,5-dioxopyrrolidin-1-yl)oxy]-2-oxoethyl}carbamate 

Relevant academic research and scientific papers

Novel urokinase inhibitors

The invention relates to the use of derivatives of 3-amidinophenylalanine as urokinase inhibitors for treating malignant tumors and the formation of metastases.

Quinoline derivatives as NK3 antagonists

The present invention relates to a novel use, in particular a novel pharmaceutical use for a series of quinoline derivatives.

Novel urokinase inhibitors

The invention relates to the use of derivatives of 3-amidinophenylalanine as urokinase inhibitors for treating malignant tumors and the formation of metastases.

Radioimaging probes and the use thereof

The present invention provides novel radioimaging probes for use in combination with clinical radioimaging techniques for the visualization of specific tissues or regions of the body. These probes can be packaged into a blood-borne delivery vehicle for targeted delivery to these specific tissues or regions. This invention further provides for the use of synthetic microemulsions or chemically modified human low-density lipoprotein (LDL), such as acetylated LDL (AcLDL), as delivery vehicles to target the radioimaging probes specifically to tissues or regions that contain high concentrations of LDL receptors.

Acetal hydroxylamine compounds

Compounds of formula (I): R1CH2(OR2)ONH2, wherein R1 is hydrogen or methyl and R2 is a C1-C6 alkyl group, or a salt thereof are useful as reagents for the synthesis of

Methods and compositions for gene delivery

The present invention provides novel compositions and formulations for delivering anionic compounds, particularly polynucleotides (DNA and RNA), across cellular boundaries (e.g., cellular membranes) either in vivo or in vitro.

Process for preparing [S- (R*, S*) ] -beta- [ [ [1- [1-oxo-3- (4-piperidinyl) propyl] -3-piperidinyl] carbonyl]amino] -3-pyridinepropanoic acid and derivatives

A process for preparing a compound of formula I wherein R1 and R2 are independently selected from the group consisting of hydrogen, lower alkyl and halogen

Peptide nucleic acids having 2,6-diaminopurine nucleobases

A novel class of compounds, known as peptide nucleic acids, bind complementary DNA and RNA strands more strongly than a corresponding DNA strand, and exhibit increased sequence specificity and binding affinity. The peptide nucleic acids of the invention comprise ligands selected from a group consisting of naturally-occurring nucleobases and non-naturally-occurring nucleobases attached to a polyamide backbone. Some PNAs of the invention also contain C1-C8alkylamine side chains.

LH-RH receptor antagonists

PCT No. PCT/JP96/01140 Sec. 371 Date Jun. 6, 1996 Sec. 102(e) Date Jun. 6, 1996 PCT Filed Apr. 25, 1996 PCT Pub. No. WO96/34012 PCT Pub. Date Oct. 31, 1996The LH-RH receptor antagonists containing cyclic pentapeptides or salts thereof and novel cyclic pentapeptide or salts thereof are provided. The LH-RH receptor antagonists of the present invention are effective as medicines for preventing and curing sex hormone-dependent cancers (e.g., prostatic cancer, uterine cancer, mammary cancer, pituitary tumor, etc.), prostatomegaly, endometriosis, hysteromyoma, puberty precox, amenorrheal syndromes, multilocular ovarian syndromes, comedo, etc. and are also effective as pregnancy controlling agents (e.g., contraceptives, etc.) and menstrual cycle controlling agents. Moreover, these are also useful in the livestock industry for the control of the estrus of animals and also for the improvement in the quality of meat and for the control of the growth of animals, as well as in the marine products industry as spawning promoters for fishes.